MaxCyte, Inc. (MXCT)
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript
MaxCyte Q1 Earnings Call Highlights
MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript
MaxCyte, Inc. (MXCT) Reports Q4 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.1 per share a year ago.
MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript
MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Maher Masoud - President, CEO & Executive Director Douglas Swirsky - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair & Company L.L.C., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Hannah Hefley - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Rohan Walcott - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good day, and thank you for standing by.
MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Hannah Webb Hefley - Stephens Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.09 per share a year ago.
MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Eric Abdel - IR Maher Masoud - President and CEO Doug Swirsky - CFO Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Mark Massaro - BTIG Chad Wiatrowski - TD Cowen Dan Arias - Stifel Operator Good day and thank you for standing by. Welcome to the MaxCyte First Quarter Earnings Conference Call.
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.10 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.09 per share a year ago.
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)
MaxCyte (MXCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround
MaxCyte (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
